Form 4: CalciMedica CMO Sudarshan Hebbar Granted 83,300 Stock Options

CalciMedica, Inc.'s Chief Medical Officer, Sudarshan Hebbar, was granted 83,300 employee stock options with an exercise price of $1.53 per share, following stockholder approval of an amended equity incentive plan.

Summary

• Sudarshan Hebbar, Chief Medical Officer of CalciMedica, Inc. (CALC), was granted 83,300 employee stock options.
• The options have an exercise price of $1.53 per share.
• The grant was approved by the Board of Directors on April 23, 2025, and subsequently by the Company's stockholders on June 24, 2025, as part of an amendment to the 2023 Equity Incentive Plan.
• The options are immediately exercisable and have an expiration date of April 22, 2035.
• Following this transaction, Mr. Hebbar beneficially owns 83,300 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a Form 4 primarily reports a transaction, the grant of options to a key executive aligns interests and is a standard, positive aspect of corporate governance and compensation, indicating stability in management and a commitment to long-term incentives. It does not, however, provide direct insight into operational performance.

Positives

• The grant of stock options aligns the Chief Medical Officer's financial interests with those of the shareholders, incentivizing long-term performance.
• The approval of the Amended 2023 Equity Incentive Plan by stockholders demonstrates good corporate governance and support for the company's compensation strategy.

Future Outlook

The document primarily reports a past transaction and does not contain specific forward-looking statements regarding the company's financial performance or strategic direction, beyond the future expiration date of the granted options.

Management Comments

• The option grant was approved by the Board of Directors of CalciMedica, Inc. on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan.

Industry Context

The granting of stock options to key executives like the Chief Medical Officer is a standard practice in the biotechnology and pharmaceutical industries. It serves as a common form of long-term incentive compensation, aiming to retain talent and align management's interests with shareholder value creation.

Comparison to Industry Standards

• The practice of granting stock options to executive officers is a widely accepted compensation strategy across the biotechnology and pharmaceutical sectors, consistent with global benchmarks for executive incentive programs.
• While specific comparable companies or projects are not detailed in this filing, the structure of this option grant (exercise price, vesting, expiration) is typical for executive compensation packages in growth-oriented biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options can lead to potential future dilution if exercised, but it also serves to align management's interests with shareholder value creation.
• Employees: This transaction reflects the company's ongoing use of equity incentive plans as part of its compensation strategy, which can positively impact employee morale and retention.

Next Steps

• The options are immediately exercisable, allowing the Chief Medical Officer to purchase common stock at the exercise price at any time before the expiration date.

Key Dates

Recommendation

Keywords

CalciMedica, CALC, Stock Option, Executive Compensation, Insider Transaction, Form 4, Sudarshan Hebbar, Chief Medical Officer, Equity Incentive Plan